Briacell Therapeutics Corp sees notable price movement as it presents robust data on its anti-cancer platform.
Briacell Therapeutics Corp (BCT.TO) has seen its stock price rise recently, closing at C$4.82, up 1.46% for the day and 17.55% for the week. This increase aligns with the company's developments in cancer immunotherapy, especially the promising results from its Bria-OTS+™ platform showcased in recent presentations.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$48.37M
52W high
$20.40
52W low
$3.68
1W change
+17.55%
Beta
1.52
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 259.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+259.7% Upside
Current Price
C$5.56
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
65.4%
Annualized
90-Day Vol
83.7%
Annualized
Trend (90d)
+40.4%
Annualized drift
90d Mean
C$6.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.83 | C$4.66 – C$7.31 |
| 60 trading days | C$6.12 | C$4.45 – C$8.42 |
| 90 trading days | C$6.42 | C$4.34 – C$9.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on Briacell's advancements in cancer treatment, as the company continues to share positive data that could impact its future performance. However, given the significant drop in its stock price year-to-date, it's wise to proceed with caution.
Briacell Therapeutics Corp stock rises 17.55% this week.
With a market cap of C$48.37 million, the stock is trading well below its 52-week high of C$20.40, which may present an opportunity for investors but also highlights the associated risks.
Bull case
The positive sentiment around Briacell is backed by strong preclinical data showing the effectiveness of its Bria-OTS+™ platform. Analysts are optimistic, with an average target price of C$20.00, indicating significant upside potential.
Bear case
On the flip side, the company is facing challenges, including a declining stock price over the year and a high beta of 1.52, which suggests increased volatility. Investors should be aware of the risks involved in investing in biotech firms, especially those in the early stages of clinical development.
Recent Price Action
Briacell Therapeutics Corp closed at C$4.82, with a 1D increase of 1.46% and a weekly gain of 17.55%. Over the past month, the stock is up 7.75%, but it remains down 43.38% year-to-date. The recent surge in trading volume, reaching 25,391 shares compared to a 20-day average of 3,527 shares, has drawn attention from investors.
Catalysts Behind the Movement
Advertisement
The recent price increase is linked to positive developments regarding Briacell's Bria-OTS+™ platform, which has shown strong anti-cancer activity in preclinical models. This data was presented at the AACR Annual Meeting, highlighting the potential effectiveness of the treatment. Such advancements are crucial as the company aims to establish itself in the competitive biotech landscape.
Technical Picture
From a technical standpoint, Briacell's stock is currently trading above its 50-day moving average of C$4.79, indicating a slight bullish trend. However, it remains significantly below its 200-day moving average of C$7.08, suggesting a longer-term bearish outlook. The stock's 52-week range is between C$3.68 and C$20.40, meaning it is currently trading at about 7% of its range. The stock's beta of 1.52 indicates higher volatility compared to the market.
Insider Activity
No recent insider activity has been reported for Briacell Therapeutics Corp, which can often indicate management's confidence in the company's future performance.
Price Action Summary
As of the last close, Briacell Therapeutics Corp stock is priced at C$4.82, reflecting a 1D increase of 1.46%. Investors should keep an eye on the ongoing developments in the company’s clinical trials and market response as it navigates its growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
